Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Jela Ivankova"'
Autor:
Monika Brunclikova, Jela Ivankova, Maria Skerenova, Tomas Simurda, Lucia Stanciakova, Ingrid Skornova, Miroslava Sterankova, Jana Zolkova, Miroslava Dobrotova, Pavol Holly, Peter Kubisz, Jan Stasko
Publikováno v:
Acta Medica Martiniana, Vol 22, Iss 1, Pp 34-44 (2022)
Introduction: Inherited platelet hyperaggregability, so called “Sticky platelet syndrome” (SPS), is a prothrombotic platelet disorder. The syndrome contributes more often to arterial than venous thrombosis. The most common localization of arteria
Externí odkaz:
https://doaj.org/article/81cad9474a4041239c0c6896498e153f
Autor:
Lucia Stanciakova MD, PhD, Miroslava Dobrotova MD, PhD, Pavol Holly MD, PhD, Jana Zolkova MSc, PhD, Lubica Vadelova MSc, PhD, Ingrid Skornova MA, PhD, Jela Ivankova MSc, Matej Samos MD, PhD, Tomas Bolek MD, PhD, Marian Grendar MSc, PhD, Jan Danko MD, PhD, Peter Kubisz MD, DSc, Jan Stasko MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Low-molecular-weight heparin (LMWH) is suggested for thromboprophylaxis in pregnant women with previous venous thromboembolism (VTE ) . Anyway, there is only limited amount of studies evaluating the effect of LMWH on hemostatic parameters during preg
Externí odkaz:
https://doaj.org/article/1446eff435f34e45a8e508419e73fd28
Autor:
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Jana Zolkova RNDr, Lenka Lisa MD, PhD, Ludmila Linekova MD, Marian Mokan MD, DSc, FRCP Edin, Jan Stasko MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery. The aim of this study was to study the anticoagulant effects of dabigatran in patients with atria
Externí odkaz:
https://doaj.org/article/45ffc6ca78f2438e8496473c24f36106
Autor:
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Lenka Lisa MD, PhD, Jana Zolkova RNDr, Lubica Vadelova RNDr, Marian Mokan Prof, MD, DSc, FRCP Edin, Jan Stasko Prof, MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to as
Externí odkaz:
https://doaj.org/article/90ee2f85093240908bd3f4c5594d9b6e
Autor:
Lucia Stanciakova, Miroslava Dobrotova, Pavol Holly, Jana Zolkova, Lubica Vadelova, Ingrid Skornova, Jela Ivankova, Tomas Bolek, Matej Samos, Marian Grendar, Jan Danko, Peter Kubisz, Jan Stasko
Publikováno v:
Diagnostics, Vol 11, Iss 5, p 828 (2021)
Thromboprophylaxis with low-molecular-weight heparin (LMWH) for patients with a history of venous thromboembolism (VTE) is suggested. Rotational thromboelastometry (ROTEM®) represents an innovative point-of-care method enabling the complex and quick
Externí odkaz:
https://doaj.org/article/d3b778e32d9946dc82b545930afbb383
Publikováno v:
Journal of Thrombosis and Thrombolysis. 49:578-583
Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f49cf3583ecb40493611b6d7add8875f
https://doi.org/10.1007/s11239-020-02093-9
https://doi.org/10.1007/s11239-020-02093-9
Publikováno v:
American Journal of Therapeutics. 27:e159-e164
Background Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that bisoprolol as significant P-glycoprotein inhibitor might interact with dabigatran. Study question To investigate the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b37b5691ba7b579d32797fb14935c828
https://doi.org/10.1097/mjt.0000000000000786
https://doi.org/10.1097/mjt.0000000000000786
Autor:
Jela Ivankova, Juraj Sokol, Jan Stasko, Ingrid Skornova, Lucia Stančiaková, Jana Zolkova, L Vadelova, Maria Skerenova, A Vazanova
Publikováno v:
Bratislava Medical Journal. 121:700-704
Aims We aimed to characterize relationship between the expression profiles of platelet miR-96, miR-126 and miR-223 and platelet function examination in patients with sticky platelet syndrome (SPS) and in healthy controls. Background MicroRNAs (miRNA,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abb4c6bfed470fefa19bce057a257dad
https://doi.org/10.4149/bll_2020_114
https://doi.org/10.4149/bll_2020_114
Autor:
Maria Skerenova, A Vazanova, Ingrid Skornova, L Vadelova, Jela Ivankova, Jan Stasko, Jana Zolkova, Juraj Sokol
Publikováno v:
Acta Medica Martiniana. 19:88-94
Introduction: Sticky platelet syndrome (SPS) is referred to as a platelet hyperaggregability triggered by low concentrations of platelet agonists adenosine diphosphate (ADP) and/or epinephrine (EPI). Platelet aggregation with other inducers (collagen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cd1a104d80b5556a00478af3a9ae038
https://doi.org/10.2478/acm-2019-0012
https://doi.org/10.2478/acm-2019-0012
Publikováno v:
American Journal of Therapeutics. 26:e649-e652
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3f6a79c5d0a22abaa35eb30550e5699
https://doi.org/10.1097/mjt.0000000000000851
https://doi.org/10.1097/mjt.0000000000000851